Health Populi

MAY 20, 2021

Year-on-year, different spikes and ups-and-downs call out for special mention, such as: Pharma’s 13-point steep dive to 38% between 2017 and 2018, dramatically recovering by 9 points in the last year to 47% [with the wild card here of whether U.S. to approve Medicare’s negotiation of drug prices with pharmaceutical companies].

BioTech 310

BioTech Pharmaceuticals Leadership Medicare 310

Health Populi

MAY 8, 2019

Medicines treating hypertension experienced the largest absolute growth in number of scripts, up 48 million in 2018 over 2017; this increase was driven by an aging population and expanded guidelines in place for the treatment of high blood pressure. In 2017, nearly 60% of new therapy starts were for the Flucelvax Quadrivalent flu vaccine.

Medicare 149

Medicare BioTech Pharmaceuticals Mental health 149

Health Populi

MAY 14, 2018

Smart Pharmaceuticals Index (NQSSPH) from May 11, 2018, the date when POTUS and Secretary Azar made their announcement. Incentives for lowering list prices for medicines, such as FDA requiring that drug companies include list prices in ads and bringing more transparency to Medicare drug pricing and generic competition, and.

Pharmaceuticals 120

Pharmaceuticals Medicare Life Science BioTech 120

Insulin Nation

DECEMBER 8, 2016

Drug pricing was not the centerpiece of his populist rhetoric, but on the campaign trail he did briefly describe his plans to have Medicare negotiate for better drug prices; he also signaled his intent to remove hurdles to importing cheaper drugs made abroad.

BioTech 56

BioTech Pharmaceuticals Medicare 56